Genmab A Accounts Receivables Turnover Ratio from the fourth quarter 2025 to the fourth quarter 2024

Quarterly Results, Trends, Rankings, Statistics

Genmab A's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 193.54, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Genmab A in Dec 31 2025 quarter, has decreased to 2 days, compared to 3 days, in the 0 quarter.

If we take a look into Healthcare sector 510 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from to 3436.

What is Receivable Turnover Ratio?
What is Genmab A Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GMAB Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2024) II. Quarter
Y / Y Receivable Change	47.69 %	-	-	-	-
Y / Y Revenue Change	169.18 %	-	104.42 %	-	71.65 %
Receivable Turnover Ratio (TTM)	193.54	141.97	204.53	123.96	137.86
GMAB's Total Ranking	# 3436	#	#	#	#
Accounts Receivable average collection period days	2	3	2	3	3
Seq. Receivable Change	-	-	-	-	-
Seq. Revenue Change	-	-	-	-	35.94 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 165
Healthcare Sector	# 511
Overall Market	# 3436

Receivable Turnover Ratio Statistics
High	Average	Low
3.82	3.17	2.5
(Dec 31 2020)		(Dec 31 2022)

GMAB Company Profile • Back to GMAB Efficiency Comparisons • Compare GMAB Receivables Turnover Ratio to its Competitors

Financial Statements
Genmab A's Accounts Receivable	$ 96 Millions	Visit GMAB's Balance sheet
Genmab A's Sales TTM	$ 4,645 Millions	Visit GMAB's Income Statement
Sources of GMAB's Revenues		Visit GMAB's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GMAB's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GMAB's Growth Rates	GMAB's Roa	GMAB's Inventory Turnover Ratio	GMAB's Dividend Comparisons
GMAB's Profitability Ratios	GMAB's Roi	GMAB's Asset Turnover Ratio	GMAB's Dividend Growth
GMAB's Valuation Ratios	GMAB's Roe	GMAB's Financial Strength Ratios	GMAB's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Bridgebio Oncology Therapeutics Inc	117.58	$ 11.347 Millions	$ 0.097 Millions
Logicmark Inc	114.88	$ 11.426 Millions	$ 0.099 Millions
Aesthetic Medical International Holdings Group Limited	112.22	$ 106.636 Millions	$ 0.950 Millions
Sbc Medical Group Holdings Incorporated	104.31	$ 171.922 Millions	$ 1.648 Millions
Harvard Apparatus Regenerative Technology Inc	100.57	$ 0.704 Millions	$ 0.007 Millions
Sangamo Therapeutics Inc	96.94	$ 39.552 Millions	$ 0.408 Millions
Caribou Biosciences Inc	94.97	$ 11.159 Millions	$ 0.118 Millions
Scisparc Ltd	85.60	$ 0.856 Millions	$ 0.010 Millions
Legend Biotech Corporation	78.54	$ 1,028.900 Millions	$ 13.100 Millions
Agape Atp Corporation	71.64	$ 1.524 Millions	$ 0.021 Millions
Aclaris Therapeutics Inc	70.50	$ 7.826 Millions	$ 0.111 Millions
Lifevantage Corp	68.03	$ 208.401 Millions	$ 3.063 Millions
Humacyte Inc	67.98	$ 40.803 Millions	$ 0.600 Millions
Crinetics Pharmaceuticals Inc	52.00	$ 7.696 Millions	$ 0.148 Millions
Galapagos Nv	51.75	$ 1,257.532 Millions	$ 24.301 Millions
Brookdale Senior Living Inc	51.27	$ 3,194.066 Millions	$ 62.298 Millions
Aim Immunotech Inc	50.29	$ 0.088 Millions	$ 0.002 Millions
Stoke Therapeutics Inc	48.58	$ 184.420 Millions	$ 3.796 Millions
Arvinas Inc	47.32	$ 262.600 Millions	$ 5.550 Millions
Eyepoint Inc	45.42	$ 31.371 Millions	$ 0.691 Millions
Vireo Growth Inc.	45.06	$ 268.769 Millions	$ 5.965 Millions
X4 Pharmaceuticals Inc	45.05	$ 35.113 Millions	$ 0.780 Millions
Fortrea Holdings Inc	44.55	$ 2,723.400 Millions	$ 61.125 Millions
Valion Bio Inc	42.84	$ 0.482 Millions	$ 0.011 Millions
Kyntra Bio Inc	41.55	$ 6.440 Millions	$ 0.155 Millions
Cytomx Therapeutics Inc	40.82	$ 76.201 Millions	$ 1.867 Millions
Atara Biotherapeutics Inc	40.31	$ 121.355 Millions	$ 3.010 Millions
Nature s Sunshine Products inc	39.85	$ 479.724 Millions	$ 12.040 Millions
National Vision Holdings Inc	39.24	$ 1,987.488 Millions	$ 50.646 Millions
Lineage Cell Therapeutics Inc	39.16	$ 14.556 Millions	$ 0.372 Millions

Date modified: 2026-10-05T11:03:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.